1. Executive Summary
1.1 Inflammatory Bowel Disease Market Review
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. What Is Inflammatory Bowel Disease?
2.1 Definition
2.2 Types of IBD
2.3 Signs, Symptoms and Associated Conditions
2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations and Other Events
2.3.2 Pyoderma Gangrenosum
2.3.3 Primary Sclerosing Cholangitis
2.4 Ulcerative Colitis
2.5 Crohn's Disease
2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
2.7 What Causes Inflammatory Bowel Disease?
2.7.1 Genetic Factors
2.7.2 Environmental Factors
2.8 How Common is Inflammatory Bowel Disease?
2.8.1 Geographical Variation in Rates of IBD
2.9 Socioeconomic Costs of IBD
2.9.1 The Individual Cost of IBD
3. Treating Inflammatory Bowel Disease
3.1 Treatment Goals
3.2 Drug Classes Used in IBD Treatment
3.2.1 Aminosalicylates
3.2.2 Corticosteroids
3.2.3 Immunomodulators
3.2.4 Monoclonal Antibodies
3.3 Surgery
3.3.1 Surgery for Ulcerative Colitis
3.3.2 Surgery for Crohn's Disease
3.4 Alternative Treatments
3.4.1 Faecal Bacteriotherapy and Pre/Probiotics
3.4.2 Helminthic Therapy
3.4.3 Complementary Medicine
3.5 Treatment Protocol
3.5.1 Recent Trial Data
4. The World Inflammatory Bowel Disease Market, 2010-2025
4.1 Non-Biologic Drugs
4.1.1 IBD-Specific Drugs (Intestinal Anti-inflammatories)
4.1.2 Drugs not Specific to IBD (Others)
4.2 Biologic Drugs
4.3 Total Market
4.4 Market Shares by Disease Type
4.5 Market Forecast: Inflammatory Bowel Disease Sales
4.6 Market Forecasts: Sales by Disease Type
4.7 Market Forecasts: Sales by Therapy Type
5. Leading Drugs for Inflammatory Bowel Disease, 2010-2025
5.1 Intestinal Anti-inflammatory Drugs
5.2 Asacol
5.2.1 Asacol: Background
5.2.2 Asacol: Sales Forecast and Analysis
5.3 Pentasa
5.3.1 Pentasa: Background
5.3.2 Pentasa: Sales Forecast and Analysis
5.4 Entocort
5.4.1 Entocort: Background
5.4.2 Entocort: Sales Forecast and Analysis
5.5 Lialda
5.5.1 Lialda: Background
5.5.2 Lialda: Sales Forecast and Analysis
5.6 Salofalk
5.6.1 Salofalk: Background
5.6.2 Salofalk: Sales Forecast and Analysis
5.7 Comparison of Intestinal Anti-inflammatory Sales Forecasts
5.8 Biologics
5.9 Remicade
5.9.1 Remicade: Background
5.9.2 Remicade: Sales Forecast and Analysis
5.10 Humira
5.10.1 Humira: Background
5.10.2 Humira: Sales Forecast and Analysis
5.11 Cimzia
5.11.1 Cimzia: Background
5.11.2 Cimzia: Sales Forecast and Analysis
5.12 Tysabri
5.12.1 Tysabri: Background
5.12.2 Tysabri: Sales Forecast and Analysis
5.13 Comparison of Biologic Sales Forecasts
6. The R&D Pipeline for Inflammatory Bowel Disease
6.1 Monoclonal Antibodies
6.1.1 HuZAF
6.1.2 Stelara
6.1.3 Vedolizumab
6.1.4 Simponi
6.2 Small Molecules
6.2.1 Tetomilast
6.2.2 Firategrast
6.3 Antibiotics
6.3.1 Rifaximin
6.3.2 Myoconda
6.4 Nicotine and Buproprion
6.5 Alicaforsen
6.6 Alequel
6.7 MAP Vaccine
6.8 Autologous Stem Cell Transplantation for Crohn's Disease
6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract
7. Leading Companies in the Inflammatory Bowel Disease Sector
7.1 The Largest Companies by Revenue in the Intestinal Anti-inflammatory Market
7.2 Procter & Gamble Pharmaceuticals (now owned by Warner Chilcott)
7.3 Shire Pharmaceuticals Group
7.4 Prometheus Laboratories
7.5 Ferring Pharmaceuticals
7.6 Kyorin Pharmaceutical
8. Geographical Breakdown of the World IBD Market, 2010-2025
8.1 Intestinal Anti-inflammatory Market: Seven Major Economies
8.2 Intestinal Anti-inflammatory Market: BRICT Countries
8.3 The Global IBD Market: Sales Forecasts by Geographical Area
8.3.1 North America: Sales Forecast, 2010-2025
8.3.2 Europe: Sales Forecast, 2010-2025
8.3.3 Africa, Asia and Australasia: Sales Forecast, 2010-2025
8.3.4 Latin America: Sales Forecast, 2010-2025
8.4 Comparison of Regional Markets: Sales Forecasts, 2010-2025
9. Inflammatory Bowel Disease Market: Opportunities and Challenges Ahead
9.1 SWOT Analysis of the World IBD Market
9.2 Market Drivers
9.2.1 Increasing Disease Incidence
9.2.2 Better Diagnosis
9.2.3 Nature of the Disease
9.2.4 Delivery Systems
9.2.5 Biologics
9.3 Market Restraints
9.3.1 Lack of Understanding of Disease Aetiology
9.3.2 Compliance
9.3.3 Limits of Biologics
9.3.4 A Cure or Vaccine?
10. Interviews with Experts
10.1 Marco Greco
10.1.1 Public Awareness of IBD
10.1.2 The Differences Between European Countries
10.1.3 Drug Companies' Involvement in Awareness Campaigns
10.1.4 Unmet Medical Needs
10.2 Dr Alan Fraser
10.2.1 Autoimmunity vs. Infection Theories
10.2.2 Monoclonal Antibodies
10.2.3 Genotyping
10.2.4 Remaining Therapeutic Gaps
10.2.5 Future Treatments
10.3 Professor Thomas Borody
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP
10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 Potential and Future of Myoconda
10.4 Professor John Hermon-Taylor
10.4.1 Significance of MAP in Crohn's
10.4.2 The Rising Incidence of IBD
10.4.3 Defining IBD
10.4.4 Timeframe of MAP Vaccine
10.4.5 Antibiotic Activity of Other Crohn's Treatments
10.4.6 Alternative Treatments
10.4.7 Ethics of Crohn's Drug Development
10.4.8 Impact of a Vaccine on the Market
10.4.9 On Claims that MAP is Not Implicated in CD
11. Conclusions of the Study
11.1 IBD Sales to 2025 - How High Will The Market Reach?
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatment
11.5 Future IBD Treatments: R&D Efforts Promising
11.6 The IBD Sector: Looking to the Future Confidently
List of Tables
Table 2.1 World Incidence Rates for IBD, 2010
Table 2.2 Prevalence of IBD in Selected Countries, 2010
Table 2.3 Common Misdiagnoses for IBD
Table 3.1 Ancillary Drug Types Used in Inflammatory Bowel Disease, 2010
Table 3.2 Composition of Various 5-ASA Drugs
Table 4.1 Inflammatory Bowel Disease Market: World Sales and Market Shares by Drug Class, 2009
Table 4.2 Studies Comparing the Direct Medical Costs of Crohn's Disease and Ulcerative Colitis
Table 4.3 World IBD Market: Sales by Disease Type, 2009
Table 4.4 World IBD Market: Sales Forecast, 2010-2025
Table 4.5 World IBD Market: Sales Forecast by Disease Type, 2010-2025
Table 4.6 World IBD Market: Sales Forecast by Therapy Type, 2010-2025
Table 5.1 Top-Five Intestinal Anti-Inflammatory Drugs: World Sales, 2009
Table 5.2 Asacol: World Sales Forecast, 2010-2025
Table 5.3 Pentasa: World Sales Forecast, 2010-2025
Table 5.4 Entocort: World Sales Forecast, 2010-2025
Table 5.5 Lialda: World Sales Forecast, 2010-2025
Table 5.6 Salofalk: World Sales Forecast, 2010-2025
Table 5.7 World Sales Forecasts for Leading Intestinal Anti-Inflammatories, 2010-2025
Table 5.8 Biologics for IBD: World Sales, 2009
Table 5.9 Remicade: World Sales Forecast, 2010-2025
Table 5.10 Contraindications for TNF-a Blockers
Table 5.11 Humira: World Sales Forecast, 2010-2025
Table 5.12 Cimzia: World Sales Forecast, 2010-2025
Table 5.13 Tysabri: World Sales Forecast, 2010-2025
Table 5.14 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Table 6.1 Key Pipeline Products for Inflammatory Bowel Disease, 2010
Table 7.1 Intestinal Anti-Inflammatories (IAIs): Largest Companies by Revenue, 2009
Table 7.2 Procter & Gamble: Major IAI Products, 2009
Table 7.3 Shire: Major IAI Products, 2009
Table 7.4 Prometheus: Major IAI Products, 2009
Table 7.5 Prometheus: Diagnostic Tests, 2009
Table 7.6 Ferring: Major IAI Products, 2009
Table 7.7 Kyorin: Major IAI Products, 2009
Table 8.1 IBD Markets of Seven Major Economies: Sales and Market Shares, 2009
Table 8.2 IBD Sales and Market Shares for the Major Emerging Markets (BRICT), 2009
Table 8.3 North America: IBD Sales Forecast, 2010-2025
Table 8.4 Europe: IBD Sales Forecast, 2010-2025
Table 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Table 8.6 Latin America: IBD Sales Forecast, 2010-2025
Table 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025
Table 9.1 SWOT Analysis of the Global IBD Market, 2010
List of Figures
Figure 2.1 Prevalence of IBD in Selected Countries, 2010
Figure 3.1 Treatment Protocols for Inflammatory Bowel Disease, 2010
Figure 4.1 World IBD Market: Sales Shares by Drug Class, 2009
Figure 4.2 World IBD Market: Sales Shares by Disease Type, 2009
Figure 4.3 World IBD Market: Sales Forecast, 2010-2025
Figure 4.4 World IBD Market: Sales Forecasts by Disease Type, 2010-2025
Figure 4.5 World IBD Market: Sales Forecasts by Therapy Type, 2010-2025
Figure 5.1 Top-Five Intestinal Anti-Inflammatories: World Market Shares, 2009
Figure 5.2 Asacol: World Sales Forecast, 2010-2025
Figure 5.3 Pentasa: World Sales Forecast, 2010-2025
Figure 5.4 Entocort: World Sales Forecast, 2010-2025
Figure 5.5 Lialda: World Sales Forecast, 2010-2025
Figure 5.6 Salofalk: World Sales Forecast, 2010-2025
Figure 5.7 World Sales Forecasts for Leading Intestinal Anti-inflammatory Drugs, 2010-2025
Figure 5.8 Biologics for IBD: World Sales, 2009
Figure 5.9 Remicade: World Sales Forecast, 2010-2025
Figure 5.10 Humira: World Sales Forecast, 2010-2025
Figure 5.11 Cimzia: World Sales Forecast, 2010-2025
Figure 5.12 Tysabri: World Sales Forecast, 2010-2025
Figure 5.13 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Figure 7.1 Intestinal Anti-Inflammatories: Largest Companies by Sales, 2009
Figure 8.1 IBD Markets of Seven Major Economies: Sales, 2009
Figure 8.2 IBD Markets of Major Emerging Markets (BRICT): Sales, 2009
Figure 8.3 North America: IBD Sales Forecast, 2010-2025
Figure 8.4 Europe: IBD Sales Forecast, 2010-2025
Figure 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Figure 8.6 Latin America: IBD Sales Forecast, 2010-2025
Figure 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025